HopeStage
Back to all studies
CompletedNCT01262170

CigRx Lozenges for Short-Term Smoking Cravings

About this titleRead the official source — NCT01262170
Interventional studyAges 23–72United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 23 years to 72 years.

Listed locations
MartinsburgSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2010
Recruitment status
Completed
Enrollment listed in the registry
109
Sponsor
Rock Creek Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Other
Intervention type
Dietary supplement, Other
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 23 Years to 72 Years
Official registry ID
NCT01262170
Official title
Show the full official title

A Randomized, Double-Blind, Active-Controlled, Crossover, Pilot Study to Evaluate the Safety and Efficacy of CigRx™ Lozenge, a Non-Nicotine Non-Tobacco Dietary Supplement, in Daily Smokers in Temporarily Reducing the Desire to Smoke

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Martinsburg

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Rock Creek Pharmaceuticals, Inc.

Who was this study for?

Listed age limits: 23 years to 72 years.

Want to explore more studies?

Explore studies